NTLA Stock Recent News
NTLA LATEST HEADLINES
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief Medical Officer Edward J. Dulac - Executive Vice President, Chief Financial Officer and Treasurer John M.
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia (NTLA) To Contact Him Directly To Discuss Their Options
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET.
An updated edition of the June 27, 2025, article.